QCMD to use virusPHIX-P9™ in its SARS-CoV-2 antigen EQA scheme

QCMD will use the universal biological sample stabilisation virusPHIX-P9™ as the matrix within its forthcoming SARS-CoV-2 antigen EQA pilot scheme. Studies have proven that virusPHIX-P9™ is both capable of inactivating SARS-CoV-2 as well as stabilizing clinical samples at ambient temperatures. Extensive testing at QCMD has shown that virusPHIX-P9™ is compatible with a variety of SARS-CoV-2 [...]